Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Glenohumeral Dislocation Arthropathy

Etiology, Diagnosis, and Management

Vezeridis, Peter S., MD; Ishmael, Chad R., MD; Jones, Kristofer J., MD; Petrigliano, Frank A., MD

JAAOS - Journal of the American Academy of Orthopaedic Surgeons: April 1, 2019 - Volume 27 - Issue 7 - p 227–235
doi: 10.5435/JAAOS-D-17-00056
Review Article
SDC

Dislocation arthropathy describes the development of progressive degenerative changes of the glenohumeral joint in the setting of instability. Although the specific etiology remains unclear, the trauma of a single dislocation, repetitive injury associated with recurrent dislocations, changes in shoulder biomechanics, and complications associated with instability surgery have all been implicated in its development. Pain and restricted range of motion are the most common patient complaints. Conservative management, consisting of pain control, activity modification, and physical therapy, is the first-line treatment after the development of arthropathy. If conservative management fails, multiple surgical options exist. Arthroscopic débridement can be attempted in young, active patients and in those patients with mild-to-moderate arthropathy. Open subscapularis lengthening and capsular release can be done in patients with prior instability repairs that are overly tight. In young patients with minimal bone loss and glenoid wear, surface replacement arthroplasty and hemiarthroplasty are surgical options. In older patients with moderate-to-severe arthropathy, total shoulder or reverse shoulder arthroplasty is the preferred treatment option. Further study is needed to better predict which patients will develop dislocation arthropathy and will thus benefit from early surgical intervention.

From the Department of Orthopaedic Surgery, University of California, Los Angeles (UCLA), Los Angeles, CA.

Dr. Jones or an immediate family member has received research or institutional support from Aesculap/B. Braun and Musculoskeletal Transplant Foundation. Dr. Petrigliano or an immediate family member is a member of a speakers' bureau or has made paid presentations on behalf of Biomet. Neither of the following authors nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Dr. Vezeridis and Dr. Ishmael.

© 2019 by American Academy of Orthopaedic Surgeons
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website